Selexipag Tablets Reference Listed Drug

* Please be kindly noted products are not for therapeutic use. We do not sell to patients.

 

Generic Name	Selexipag Tablets
Brand Name	Uptravi
Dosage Form	Tablet
Strength	0.4mg
MAH of Product	Janssen-Cilag International NV
Note 1	Original drug not imported to China
Note 2	EU Listing
Product Type	Reference Listed Drugs (RLDs)

 

UPTRAVI is indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH.

Compared with the prostacyclins already on the market for the treatment of pulmonary arterial hypertension, Selexipag Tablets are the first oral formulation that can improve patient compliance. This product is convenient to use, avoids the injection site reaction of intravenous administration, and avoids throat irritation and coughing of inhalation dosage forms.

 

We are a global professional supplier of Reference Listed Drug products for pharmaceutical companies conducting clinical trials and CROs, featuring high-quality services and competitive prices. You can get the most favorable Reference Listed Drug prices here. If you have a designated listing country, licensee, or other requirements, please send us the detailed requirements and we will help you purchase through global supplier resources.

 

Email: tosun-global@upharm.cn

Wechat/WhatsApp: (+86)189-2212-0575

Hot Tags: Selexipag Tablets Reference Listed Drug, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Esomeprazole Magnesium Enteric Coated Capsules, Alfacalcidol Soft Capsules, Olanzapine Tablets, Acarbose Tablets, Reference Listed Drugs, Adefovir Dipivoxil Tablets

• Previous: Docusate Sodium Tablets Reference Listed Drug
• Next: Trifluridine And Tipiracil Hydrochloride Tablets Reference Listed Drug